Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...
The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...
Baptist Memorial Hospital–Attala is expanding access to cancer care and other outpatient treatments through its Infusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback